PHADIA AB
5 recall(s) on record — most severe on record: Class II.
Recalls by year
- Recalls (5)
Registered facilities (4)
- PHADIA GMBH FEI 3005774014 · DE
- PHADIA US INC. FEI 3004973408 · MI
- PHADIA AB FEI 3002807876 · SE
- PHADIA AB FEI 3039353646 · SE
Recalls & enforcement
- Class IIOngoing2023-05-24Complaints that specific samples produced false positive EliA GBM results. A positive signal was present when these samples were tested for coating-solution reactivity using EliA wells without antigen.
- Class IITerminated2019-07-09code 7-102 Liquid Sensor Error
- Class IITerminated2019-05-10Potential for reporting low assay results
- Class IITerminated2017-11-20We want to inform all Phadia 250 system operators performing EliA Assays not to use the function OK to All in any version of Phadia Prime, up to and including 2.1.4, when rejecting and retesting samples with any EliA assay (the OK function may be used for rejecting single tes…
- Class IITerminated2015-12-28All equivocal and positive results (greater or equal 7 EliA U/ml) on EliA SmDP well lot 0018 may be incorrect and must be considered invalid. Patient samples in complaint investigations caused unspecific signals up to 22 U/ml on EliA SmDP well lot 0018. The nonspecific signals ar…
Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. We restate the public record only — measured facts, never risk verdicts.
Cite this record
RegWarden. “PHADIA AB — FDA compliance profile.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/company/oo-9004441-phadia-ab/
Alerts for PHADIA AB
Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.
Want a one-page facility brief?
A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.